000168639 001__ 168639
000168639 005__ 20260212205631.0
000168639 0247_ $$2doi$$a10.1097/TP.0000000000005554
000168639 0248_ $$2sideral$$a148065
000168639 037__ $$aART-2025-148065
000168639 041__ $$aeng
000168639 100__ $$aMartínez-Arenas, Laura
000168639 245__ $$aThe Relentless Progression of Metabolic Dysfunction–associated Steatotic Liver Disease in Liver Transplantation in Spain
000168639 260__ $$c2025
000168639 5060_ $$aAccess copy available to the general public$$fUnrestricted
000168639 5203_ $$aBackground.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly recognized as a significant indication for liver transplantation (LT) in North America. Yet data on its impact in other countries, such as Spain, remain limited. This study aimed to evaluate the prevalence and trajectory of MASLD-related LT in Spain and compare these findings with broader national data and international data sets.
Methods.
Multicenter retrospective cohort study including adults (18 y and older) undergoing LT for MASLD between 2010 and 2023 in 5 large Spanish centers. Additional data were obtained from the Spanish Transplant Registry (Organización Nacional de Trasplantes) and high-prevalence LT centers in the United States (n = 7) and Canada (n = 1).
Results.
Among 3448 LTs performed in the 5 Spanish centers, 3.4% (n = 117) were MASLD-related. An increasing trajectory of MASLD-related LT was observed, with predictions suggesting a rise to 5.4%–10.8% of LTs for MASLD by 2028. These trends were consistent with Organización Nacional de Trasplantes data. Compared with North American data, the growth trajectory in Spain showed a less steep increase. Hepatocellular carcinoma rates were higher in the Spanish MASLD-LT recipients, yet metabolic comorbidities were frequent in all populations.
Conclusions.
The burden of MASLD-related LT in Spain is growing, yet at a less pronounced rate than in the United States/Canada. Whether this slower increase will persist or decline in the future as newer antiobesity and MASLD-related drugs are increasingly used is still unknown. In the meantime, our results highlight the need for tailored approaches to management and prevention in the Spanish population and underscore the importance of continued monitoring and research into the evolving impact of MASLD on LT in Spain and beyond.
000168639 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000168639 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168639 700__ $$aCarvalho-Gomes, Ângela
000168639 700__ $$aVidal, Enrique
000168639 700__ $$aBrandman, Danielle
000168639 700__ $$aElwir, Saleh
000168639 700__ $$aSiddiqui, Mohammad S.
000168639 700__ $$aSatapathy, Sanjaya K.
000168639 700__ $$aSmith, Coleman
000168639 700__ $$aRinella, Mary E.
000168639 700__ $$aDíaz-Fontenla, Fernando
000168639 700__ $$0(orcid)0000-0003-4672-8083$$aLorente, Sara$$uUniversidad de Zaragoza
000168639 700__ $$aGuerrero-Misas, Marta
000168639 700__ $$aHerrero, Ignacio
000168639 700__ $$aSelzner, Nazia
000168639 700__ $$aWatt, Kymberly D.
000168639 700__ $$aBerenguer, Marina
000168639 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168639 773__ $$g110, 2 (2025), e444-e452$$pTransplantation$$tTransplantation$$x0041-1337
000168639 8564_ $$s1623920$$uhttps://zaguan.unizar.es/record/168639/files/texto_completo.pdf$$yVersión publicada
000168639 8564_ $$s3071707$$uhttps://zaguan.unizar.es/record/168639/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168639 909CO $$ooai:zaguan.unizar.es:168639$$particulos$$pdriver
000168639 951__ $$a2026-02-12-20:38:31
000168639 980__ $$aARTICLE